Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Mirjana Rajer, MD, PhD, Institute of Oncology Ljubljana, Ljubljana, Slovenia, provides an overview of the most common toxicities associated with checkpoint inhibitors in lung cancer, including skin pulmonary, gastrointestinal and endocrine, and how these are managed. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.